DHL Group will invest €2bn (US$2.2bn) in its its new DHL Health Logistics sector brand, to bolster its life sciences and healthcare logistics services over the next five years as part of its ‘Strategy 2030’ that aims to strengthen its position in global logistics.
Through, half of the investment will be allocated to the Americas, with 25% going to the Asia-Pacific region and 25% to the EMEA region, helping DHL expand its global footprint to deliver integrated, faster, more reliable and patient-centric logistics solutions to the healthcare sector.
The investment will focus on enhancing high-quality infrastructure and technology across all logistics touchpoints – from storage, order fulfillment and distribution to global shipping and last-mile delivery – creating more resilient, scalable and responsive supply chains for customers.
A significant part of the investment will be allocated to establishing new cross-divisional GDP-certified Pharma Hubs for multi-temperature shipments lanes, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions to ensure sustainable delivery.
DHL is also investing in high-quality, specialized cooling infrastructure to accommodate low and ultralow temperature ranges. Additionally, the Group will implement cutting-edge IT systems that provide end-to-end visibility, ensuring product integrity, regulatory compliance and confidence for healthcare providers and their patients.
“Similar to DHL Group’s purpose of ‘Connecting people, improving lives’, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” said Oscar de Bok, CEO of DHL Supply Chain.
“We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”
In addition to infrastructure investments, DHL Group has recently acquired Cryopdp, a leading specialty courier focused on clinical trials, biopharma and cell and gene therapies, to further strengthen its capabilities in this segment and expand the potential of its pharma specialized network as part of the overall investment strategy.